<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>In-situ priming of tissue-resident immunity drives durable systemic control (IP-TRM theory) - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-19</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-19</p>
                <p><strong>Name:</strong> In-situ priming of tissue-resident immunity drives durable systemic control (IP-TRM theory)</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> Delivering immune checkpoint blockade while the macroscopic tumor and its intact draining lymphatic network remain in place reactivates tumor-resident memory T cells (TRM) and facilitates robust dendritic cell-mediated cross-priming in the tumor-draining lymph node (DLN). This in-situ priming expands tumor-reactive TCR clonotypes, induces interferon-programmed effector states, and triggers antigen spreading. The neoadjuvant-primed immunity persists systemically after resection and underlies the superior event-free survival (EFS) observed with neoadjuvant-plus-adjuvant (perioperative) immunotherapy compared with adjuvant-only delivery of the same agents.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In neoadjuvant PD-1 trials, early (2–3 weeks) peripheral IFN-stimulated gene signatures and CD8+Ki67+ expansion will correlate with MPR and 2-year EFS, outperforming baseline-only biomarkers (extension of the Huang observation).</li>
                <li>Spatial profiling will reveal enriched TRM–DC neighborhoods (e.g., CXCL13+TRM adjacent to CCR7+ DCs) in neoadjuvant responders versus non-responders.</li>
                <li>TCR sequencing will show increased clonal overlap between tumor TRM and circulating TEM after the first neoadjuvant dose in patients who achieve MPR, persisting into the adjuvant phase.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Single-dose neoadjuvant PD-1 followed by immediate surgery and abbreviated adjuvant therapy will be non-inferior in EFS to longer neoadjuvant courses in patients with high baseline IFN-γ signatures, enabling toxicity reduction.</li>
                <li>Adding a local DC agonist (e.g., CD40 agonist) to neoadjuvant PD-1 will increase antigen spreading breadth and raise MPR rates beyond dual ICI alone.</li>
                <li>Personalized neoantigen vaccination given with neoadjuvant PD-1 will increase long-term clonal persistence and reduce distant metastasis risk compared with PD-1 alone.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>A randomized study showing no EFS difference between neoadjuvant+adjuvant and adjuvant-only PD-1 when total exposure and selection are matched would challenge the centrality of in-situ priming.</li>
                <li>Demonstrating no increase in TRM activation/abundance or TRM–DC interactions in neoadjuvant responders compared with adjuvant-only would refute the TRM/DLN mechanism.</li>
                <li>Showing that TCR clonal breadth and antigen spreading do not differ between neoadjuvant responders and adjuvant-only responders despite EFS differences would undermine the proposed mechanism.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Direct human measurements of TRM↔DC synapses and dynamic clonal replacement versus reactivation post-neoadjuvant therapy are limited in current datasets. </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>